Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System

NCT06937996 is registered in ClinicalTrials.gov with Englewood Hospital and Medical Center as lead sponsor.

NCT NCT06937996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System
Lead sponsor
Englewood Hospital and Medical Center
Phase
Observational
Overall status
Recruiting
Start date
May 13, 2025
Completion date
May 31, 2035
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer non-resectable